{"id":11222,"date":"2020-08-19T00:00:00","date_gmt":"2020-08-19T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/asco-2020-la-suite\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"asco-2020-la-suite","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/08\/19\/asco-2020-la-suite\/","title":{"rendered":"ASCO 2020 LA SUITE"},"content":{"rendered":"<p>\u00c0 la fin du mois de mai, de nombreux chercheurs se seraient normalement rendus \u00e0 Chicago pour la 56&nbsp;<sup>e<\/sup>&nbsp;conf\u00e9rence annuelle de l\u2019&nbsp;<em>American Society of Clinical Oncology<\/em>&nbsp;(ASCO) pour se renseigner sur les plus r\u00e9cents progr\u00e8s de la recherche sur le my\u00e9lome, en compagnie de milliers d\u2019autres chercheurs sp\u00e9cialis\u00e9s dans l\u2019\u00e9tude de diff\u00e9rents cancers.&nbsp;Au lieu d&rsquo;une rencontre en personne, la conf\u00e9rence s&rsquo;est tenue virtuellement.<\/p>\n<p>Voici quelques informations \u00e0 retenir&nbsp;:<\/p>\n<ul>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=22\" target=\"_blank\" rel=\"noopener\">Th\u00e9rapie CAR-T&nbsp;: JNJ-4528 (page 22)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=23\" target=\"_blank\" rel=\"noopener\">Anticorps monoclonal bisp\u00e9cifique se liant \u00e0 BCMA&nbsp;: Teclistanab (page 23)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=42\" target=\"_blank\" rel=\"noopener\">KRd par rapport \u00e0 VRd pour le traitement initial d\u2019un my\u00e9lome nouvellement diagnostiqu\u00e9 (page 42)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=44\" target=\"_blank\" rel=\"noopener\">DREAMM-6&nbsp;: S\u00e9curit\u00e9 et tol\u00e9rabilit\u00e9 du belantamab mafodotine en association avec Vd pour traiter le my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire (page 44)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=42\" target=\"_blank\" rel=\"noopener\">Taux de vaccination des personnes atteintes d\u2019un my\u00e9lome dans le monde et impact sur l\u2019infection, l\u2019hospitalisation et la mortalit\u00e9 (page 42)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/roomc.co\/wp-content\/uploads\/ASCO20.pdf#page=43\" target=\"_blank\" rel=\"noopener\">Vaccination et utilisation d\u2019antibiotiques d\u00e9clar\u00e9es par les patients atteints d\u2019un my\u00e9lome (page 43)<\/a><br \/>\n\t&nbsp;<\/li>\n<li><a href=\"https:\/\/www.onclive.com\/view\/raje-relays-recent-developments-in-multiple-myeloma\" target=\"_blank\" rel=\"noopener\">Raje rapporte les d\u00e9veloppements r\u00e9cents par rapport au my\u00e9lome multiple<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u00c0 la fin du mois de mai, de nombreux chercheurs se seraient normalement rendus \u00e0 Chicago pour la 56&nbsp;e&nbsp;conf\u00e9rence annuelle de l\u2019&nbsp;American Society of Clinical Oncology&nbsp;(ASCO) pour se renseigner sur les plus r\u00e9cents progr\u00e8s de la recherche sur le my\u00e9lome, en compagnie de milliers d\u2019autres chercheurs sp\u00e9cialis\u00e9s dans l\u2019\u00e9tude de diff\u00e9rents cancers.&nbsp;Au lieu d&rsquo;une rencontre [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11222","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11222"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11222\/revisions"}],"predecessor-version":[{"id":31313,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11222\/revisions\/31313"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}